In vitro delivery of a sparingly water soluble compound from PLA50 microparticles.
The administration of a sparingly soluble drug is always problematic, especially when the drug has to be released from the degradable matrix of a polymeric drug delivery system. Attempts were made to achieve the complete release of 1-[2-(fluorobenzoyl) aminoethyl]-4-(7-methoxynaphtyl)piperazine (FAMP), a potential anxiolytic and antidepressor hydrophobic compound, from racemic poly(lactic acid) (PLA50)-based microparticles, 100% release was required at a low rate in order to allow monthly repeated S.C. or I.M. injections of this potent compound. FAMP-polymer combinations were made in the form of microspheres by the solvent evaporation technique. Release profiles were investigated under dynamic conditions by using a constant flow rate of pH 7.4 0.15 M phosphate buffer, used as a model of body fluids. Under these conditions, none of the microsphere compositions led to total release within a month, even when hydrophilic excipients, namely fructose and PEG were added. PLA50-FAMP microparticles with compositions and sizes similar to those of the microspheres, were then made by direct blending in dichloromethane, evaporation of the solvent, grinding and sieving. These formulations also failed in providing total drug release within 30 days, even at a high drug load. FAMP/PLA50/water-soluble additive, ternary grounded particles were finally prepared with fructose, PLA50 oligomers or poly(ethylene glycol) (PEG) as the additive. Only PLA50 grounded particles with percolating FAMP-PEG microdomains allowed 100% release of FAMP over a 30 day period, at a quasi constant rate which depended primarily on solubility and channelling provided the flow was slow enough. Data are discussed in terms of the accessibility of the entrapped drug to the aqueous medium.
Mallard
C
C
Centre de Recherches sur les Biopolymères Artificiels, Faculty of Pharmacy, Montpellier, France.
Coudane
J
J
Rault
I
I
Vert
M
M
D014151:Anti-Anxiety Agents / Q000737:chemistry / Q000378:metabolism; D000928:Antidepressive Agents / Q000737:chemistry / Q000378:metabolism; D001549:Benzamides / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D001672:Biocompatible Materials / Q000737:chemistry; D002214:Capsules / Q000737:chemistry; D003460:Crystallization; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D004655:Emulsions; D005079:Excipients; D005632:Fructose; D007700:Kinetics; D019344:Lactic Acid / Q000737:chemistry; D008752:Methylene Chloride; D010879:Piperazines / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D011091:Polyesters; D011092:Polyethylene Glycols; D011108:Polymers / Q000737:chemistry; D012995:Solubility; D012997:Solvents; D014867:Water
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D001549:Benzamides; D001672:Biocompatible Materials; D002214:Capsules; D003692:Delayed-Action Preparations; D004655:Emulsions; D005079:Excipients; D010879:Piperazines; D011091:Polyesters; D011108:Polymers; D012997:Solvents; D014867:Water; C092824:1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride; D005632:Fructose; D019344:Lactic Acid; D011092:Polyethylene Glycols; C033616:poly(lactide); D008752:Methylene Chloride